公开(公告)号：US20070004635A1

公开(公告)日：2007-01-04

申请号：US11443868

申请日：2006-05-31

Applicant: Janice Albrecht ,  Mark Laughlin ,  Bruce Malcolm

Inventor： Janice Albrecht ,  Mark Laughlin ,  Bruce Malcolm

IPC: A61K38/08

CPC classification number: A61K31/40 ,  A61K38/08 ,  C07K5/0802 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/1005 ,  C07K5/101 ,  C07K5/1016 ,  C07K7/06

Abstract: A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.

Abstract translation: 在丙型肝炎病毒（HCV）与丙型肝炎病毒（HCV）为基因型1和/或患者之前的治疗，预防或改善一种或多种与干扰素治疗有关的症状的方法，以前的干扰素治疗无效 治疗与HCV相关的一种或多种症状，其包括向所述患者施用有效量的至少一种下列结构式为其的式I-XXVI化合物或其药学上可接受的盐，溶剂合物或酯。 还考虑了所述至少一种化合物与干扰素或聚乙二醇化干扰素和/或ribaviron的任选组合给药。

公开(公告)号：US20060276405A1

公开(公告)日：2006-12-07

申请号：US11443923

申请日：2006-05-31

Applicant: Janice Albrecht

Inventor： Janice Albrecht

IPC: A61K38/05 ,  A61K38/04 ,  A61K31/4709

CPC classification number: A61K31/4709 ,  A61K38/04 ,  A61K38/05 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods of treating hepatitis C are provided comprising using a therapeutically effective amount of at least one novel hepatitis C (“HCV”) protease inhibitor or, alternatively, at least one antiviral or immuno-modulating HCV agent, which is not an HCV protease inhibitor, for a first treatment period. Subsequently, a combination of the at least one novel hepatitis C (“HCV”) protease inhibitor and the at least one antiviral or immuno-modulating HCV agent are administered in a therapeutically effective amount for a second treatment period. The methods are provided for treating a wide variety of diseases, disorders and symptoms associated with hepatitis C virus by modulating the activity of HCV protease (for example HCV NS3/NS4a serine protease) in a subject.

Abstract translation: 提供了治疗丙型肝炎的方法，其包括使用治疗有效量的至少一种新型丙型肝炎（“HCV”）蛋白酶抑制剂或至少一种不是HCV蛋白酶抑制剂的抗病毒或免疫调节性HCV药剂， 第一疗程。 随后，将至少一种新型丙型肝炎（“HCV”）蛋白酶抑制剂和至少一种抗病毒或免疫调节性HCV试剂的组合以治疗有效量施用于第二治疗期。 提供了通过调节受试者中HCV蛋白酶（例如HCV NS3 / NS4a丝氨酸蛋白酶）的活性来治疗与丙型肝炎病毒相关的各种疾病，病症和症状的方法。

公开(公告)号：US20060276407A1

公开(公告)日：2006-12-07

申请号：US11444109

申请日：2006-05-31

Applicant: Janice Albrecht ,  Clifford Brass

Inventor： Janice Albrecht ,  Clifford Brass

IPC: A61K38/05 ,  A61K38/04 ,  A61K31/4709

CPC classification number: A61K38/04 ,  A61K31/4709 ,  A61K38/05 ,  A61K38/06 ,  A61K38/08 ,  A61K38/12

Abstract: Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating activity of HCV protease, or inhibiting cathepsin activity in a subject using the same, in which the mean volume of distribution/bioavailability (Vd/F) of the compound as measured in the plasma of the subject is greater than about 1000 L.

Abstract translation: 提供组合物和治疗组合，包括至少一种选自本文定义的式I至XXVI化合物的化合物以及治疗，预防或改善丙型肝炎一种或多种症状的方法，治疗与HCV相关的病症 病毒，调节HCV蛋白酶的活性或抑制组织蛋白酶活性，其中在受试者血浆中测量的化合物的平均体积分数/生物利用度（Vd / F）大于约1000L 。

公开(公告)号：US20060257365A1

公开(公告)日：2006-11-16

申请号：US11478879

申请日：2006-06-30

Applicant: Janice Albrecht

Inventor： Janice Albrecht

IPC: A61K38/21 ,  A61K31/7056

CPC classification number: A61K38/212 ,  A61K31/7056 ,  A61K38/21 ,  Y10S514/894 ,  A61K2300/00

Abstract: There is disclosed a method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.